Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.

Journal of neuro-oncology - 1 Sept 2015

Juratli Tareq A, Lautenschläger Tim, Geiger Kathrin D, Pinzer Thomas, Krause Mechthild, Schackert Gabriele, Krex Dietmar

Abstract excerpt

Isocitrate dehydrogenase (IDH) mutations are beginning to drive decisions on therapy for glioma patients. Here we sought to determine the impact of adjuvant treatment in patients with IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma (sHGA) WHO grades III/IV. Clinical data of 109 sHGA patients grades III/IV, in addition to IDH mutation-, 1p/19q-codeletion- and MGMT-promoter methylation status-were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Chemoradiotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Isocitrate Dehydrogenase

Share to Kaplan-Meier Estimate

Share to Neoplasm Grading

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 26033545
DOI: 10.1007/s11060-015-1822-1

Genes

MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.PMID 26033545Read ↗

The prognosis of gliomas with different molecular subtypes in the era of intensity-modulated radiation therapy (IMRT).Semantic proximity Read ↗

Correlation of Molecular Markers in High Grade Gliomas with Response to Chemo-Radiation.Semantic proximity Read ↗

Real-World Survival Outcomes After (Chemo)radiotherapy for WHO 2021-Classified Gliomas: A Multicenter Analysis of Clinical, Treatment-Related, Dosimetric, and Hematologic Prognostic FactorsSemantic proximity Read ↗

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.Semantic proximity Read ↗

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.Semantic proximity Read ↗

Prognostic or predictive value of <i>MGMT</i> promoter methylation in gliomas depends on <i>IDH1</i> mutationSemantic proximity Read ↗

DNA methylation and survival differences associated with the type of IDH mutation in 1p/19q non-codeleted astrocytomasSemantic proximity Read ↗

Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profiling.Semantic proximity Read ↗

IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.Semantic proximity Read ↗

Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy.Semantic proximity Read ↗

Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.Semantic proximity Read ↗

Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.